NCT04689282View on ClinicalTrials.gov

Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Language DelayLanguage; Developmental Disorder, ExpressiveLanguage; Developmental Disorder, ReceptiveAutism Spectrum DisorderAttention Deficit-Hyperactivity DisorderSpeech Disorders in Children
Interventions
BIOLOGICAL

Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).

Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.

Trial Locations (1)

630099

Institute of Fundamental and Clinical Immunology, Novosibirsk

All Listed Sponsors
lead

Russian Academy of Medical Sciences

OTHER

NCT04689282 - Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders | Biotech Hunter | Biotech Hunter